Egerer G, Sauerland K, Ho A D
Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Hospitalstr. 3, 69115 Heidelberg, Germany.
Leuk Lymphoma. 2001 Jul;42(3):551-3. doi: 10.3109/10428190109064616.
The chimeric human mouse antibody rituximab represents a substantial advance over the use of unmodified murine antibodies. Multicenter trials showed that rituximab induced remission in 48% of 166 relapsed lymphoma patients with minimal toxicity. Thus, the antibody might play a role in patients who cannot tolerate chemotherapy because of marrow aplasia. We observed a continuous complete remission induced by rituximab alone in a 72 year old patients with refractory and progressive high-grade non-Hodgkin's lymphoma (NHL) in the phase of chemotherapy induced marrow aplasia.
嵌合型人鼠抗体利妥昔单抗相较于未修饰的鼠源抗体有了实质性的进步。多中心试验表明，利妥昔单抗使166例复发淋巴瘤患者中的48%获得缓解，且毒性极小。因此，该抗体可能对因骨髓发育不全而无法耐受化疗的患者有作用。我们观察到，在一名72岁难治性进行性高级别非霍奇金淋巴瘤（NHL）患者化疗诱导骨髓发育不全阶段，单用利妥昔单抗可诱导持续完全缓解。
